The estimated Net Worth of R. La Duane Clifton is at least 719 千$ dollars as of 13 January 2023. Mr. Clifton owns over 635 units of Zevra Therapeutics Inc stock worth over 53,899$ and over the last 14 years he sold KMPH stock worth over 0$. In addition, he makes 664,926$ as Chief Financial Officer、 Treasurer、 Secretary at Zevra Therapeutics Inc.
Sign up
Mr. Clifton KMPH stock SEC Form 4 insiders trading
R has made over 27 trades of the Zevra Therapeutics Inc stock since 2011, according to the Form 4 filled with the SEC. Most recently he bought 635 units of KMPH stock worth 3,689$ on 13 January 2023.
The largest trade he's ever made was buying 12,250 units of Zevra Therapeutics Inc stock on 27 December 2019 worth over 5,145$. On average, R trades about 1,171 units every 91 days since 2010. As of 13 January 2023 he still owns at least 9,277 units of Zevra Therapeutics Inc stock.
You can see the complete history of Mr. Clifton stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
R. LaDuane Clifton biography
R. LaDuane Clifton CPA serves as Chief Financial Officer, Treasurer, Secretary of the Company. Mr. Clifton has served as our chief financial officer since June 2015 and as our secretary and treasurer since February 2016. Previously, Mr. Clifton served as our vice president of finance and corporate controller from April 2015 to June 2015. Prior to joining our company, Mr. Clifton served in a variety of positions with The LGL Group, Inc., a publicly held producer of industrial and commercial products and services, from August 2009 to February 2015, including chief financial officer, secretary and treasurer from December 2012 to February 2015, chief accounting officer and secretary from March 2010 to December 2012, and corporate controller from August 2009 to March 2010. From August 2008 to August 2009, Mr. Clifton served as the chief financial officer of a21, Inc., a publicly held holding company with businesses in stock photography and the online retail and manufacture of framed art, and as its corporate controller from March 2007 to August 2008. Mr. Clifton served in a variety of finance and medical cost analysis roles with Aetna, Inc., a publicly held provider of healthcare benefits, from August 1991 to August 2004. Mr. Clifton was an auditor with KPMG, LLP from August 2004 to March 2007. Mr. Clifton received his B.B.A. and M.B.A. degrees from the University of North Florida and is a certified public accountant in the state of Florida.
What is the salary of R Clifton?
As the Chief Financial Officer、 Treasurer、 Secretary of Zevra Therapeutics Inc, the total compensation of R Clifton at Zevra Therapeutics Inc is 664,926$. There are 3 executives at Zevra Therapeutics Inc getting paid more, with Travis Mickle having the highest compensation of 1,360,170$.
How old is R Clifton?
R Clifton is 47, he's been the Chief Financial Officer、 Treasurer、 Secretary of Zevra Therapeutics Inc since 2016. There are 7 older and 5 younger executives at Zevra Therapeutics Inc. The oldest executive at Zevra Therapeutics Inc is Richard W. Pascoe, 57, who is the Exec. Chairman.
What's R Clifton's mailing address?
R's mailing address filed with the SEC is C/O KEMPHARM, INC., 1180 CELEBRATION BOULEVARD, SUITE 103, CELEBRATION, FL, 34747.
Insiders trading at Zevra Therapeutics Inc
Over the last 10 years, insiders at Zevra Therapeutics Inc have traded over 0$ worth of Zevra Therapeutics Inc stock and bought 3,083,371 units worth 9,282,809$ . The most active insiders traders include Street Capital Master Fund,...、David S Tierney、Travis C Mickle. On average, Zevra Therapeutics Inc executives and independent directors trade stock every 39 days with the average trade being worth of 246,727$. The most recent stock trade was executed by R. La Duane Clifton on 13 January 2023, trading 635 units of KMPH stock currently worth 3,689$.
What does Zevra Therapeutics Inc do?
KemPharm is a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs to treat serious medical conditions through its proprietary LAT™ (Ligand Activated Therapy) technology. KemPharm utilizes its proprietary LAT™ technology to generate improved prodrug versions of FDA-approved drugs as well as to generate prodrug versions of existing compounds that may have applications for new disease indications. KemPharm's prodrug product candidate pipeline is focused on the high need areas of attention deficit hyperactivity disorder, or ADHD, and stimulant use disorder. KemPharm's co-lead clinical development candidates for the treatment of ADHD, KP415 and KP484, are both based on a prodrug of d-methylphenidate, but have differing duration/effect profiles. In addition, KemPharm has received FDA approval for APADAZ®, an immediate-release combination product containing benzhydrocodone, a prodrug of hydrocodone, and acetaminophen.
What does Zevra Therapeutics Inc's logo look like?
Complete history of Mr. Clifton stock trades at Zevra Therapeutics Inc、LGL Inc
Zevra Therapeutics Inc executives and stock owners
Zevra Therapeutics Inc executives and other stock owners filed with the SEC include:
-
Travis Mickle,
Chairman of the Board, President, Chief Executive Officer -
Dr. Travis C. Mickle Ph.D.,
Co-Founder, Pres, CEO & Director -
Sven Guenther,
Executive Vice President - Research and Development -
R. LaDuane Clifton,
Chief Financial Officer, Treasurer, Secretary -
Dr. Travis C. Mickle,
Co-Founder, Chairman, Pres & CEO -
Dr. Sven Guenther,
Exec. VP of R&D -
R. LaDuane Clifton CPA,
CFO, Sec. & Treasurer -
Richard W. Pascoe,
Exec. Chairman -
Jason Rando,
IR Contact Officer -
David Tierney,
Independent Director -
Joseph Saluri,
Independent Director -
Matthew Plooster,
Independent Director -
Richard Pascoe,
Lead Independent Director -
Timothy Sangiovanni,
Vice President, Corporate Controller -
Timothy J. Sangiovanni CPA,
VP & Corp. Controller -
Dr. Andrew Barrett,
VP of Scientific Affairs -
Christal M. M. Mickle,
Co-Founder and VP of Operations & Product Devel. -
Tracy M Woody,
Chief Commercial Officer -
Danny L Thompson,
Director -
Gordon K Johnson,
Chief Business Officer -
Daniel L Cohen,
EVP, Govt. & Public Relations -
Christal M M Mickle,
Chief Product Dev. Officer -
Joshua Schafer,
CCO & EVP, Bus. Development -
Samuel J Braun,
10% owner -
Tamara A Favorito,
Director